Johnson & Johnson
Johnson & Johnson Tylenol Crisis Response
Estimated impact: $100M recall cost; brand value preserved; set industry safety standard
When seven people died from cyanide-laced Tylenol capsules in 1982, J&J faced a decision that could destroy their most profitable product. Against the advice of the FBI and FDA (who recommended against a recall), J&J CEO James Burke ordered an immediate nationwide recall of 31 million bottles ($100M cost). The company redesigned packaging with tamper-evident seals, offered free replacements, and communicated transparently. Within a year, Tylenol recaptured 30% market share. The decision became the gold standard for corporate crisis management.
Decision context
Whether to recall all Tylenol products nationwide (at massive cost) or follow FBI/FDA guidance to limit the response to the Chicago area where deaths occurred.
Biases present in the decision
Reference class base rates
Across all 146 curated case studies in our library:
Lessons learned
- Loss aversion (protecting revenue) was actively managed by framing the decision through the company's Credo values rather than through financial impact.
- Authority bias from government agencies (FBI/FDA) was overridden by a CEO who prioritized consumer safety over institutional recommendations.
- The honest mirror pattern — publicly acknowledging a crisis and taking decisive action — generated more brand trust than any amount of defensive communication.
Source: Harvard Business School Case 9-583-043 (1983); "The Tylenol Crisis" Chicago Tribune series (1982); J&J Annual Report (1983) (Case Study)
See what we'd flag in your next strategic memo.
Upload a strategic memo or board deck. Get the same bias audit you just saw for Johnson & Johnson, on your own high-stakes call, in under 60 seconds.
Or leave your email, we'll run a strategic memo of your choosing and send the readout within a business day.
Ready to audit your own memo right now? Create a free account →